Relmada Therapeutics P/E 2024

Relmada Therapeutics Aktienanalyse

What does Relmada Therapeutics do?

Relmada Therapeutics Inc is a biopharmaceutical company specializing in the development of medications for a variety of chronic pain and mental health disorders. The company is headquartered in New York, USA, and was founded in 2004. The history of Relmada Therapeutics Inc began with a focus on the development of NMDA receptor antagonists for the treatment of neuropathic pain. The company's main drug, d-Methadone, has been successfully tested in a Phase IIa clinical study and is now being tested in Phase IIb studies. Relmada Therapeutics Inc's business model is based on the development and commercialization of novel drugs targeting high medical needs. The company has a strong pipeline of pharmaceutical products in various clinical phases that can be used in pain management and mental health promotion. Relmada Therapeutics Inc generates revenue through the sale of patents and the out-licensing of their products to other pharmaceutical companies. In addition, the company pursues partnerships and joint ventures with other companies to further develop and market their products. Relmada Therapeutics Inc operates in three main divisions: pain therapy, mental health, and oncology. In pain therapy, the company has its main products, such as Oral Methadone and LevoCap ER, which help patients alleviate chronic pain. LevoCap ER is a long-acting, non-addictive pain medication that increases effectiveness and safety compared to other opioids. In the mental health field, Relmada Therapeutics Inc has developed QN-19, an overactive NMDA receptor blocker that represents a potential treatment option for depressive disorders. The company has also developed its new technology platform, mGluR2/3 agonists, which can be used in the treatment of anxiety and depression. In the oncology division, the company focuses on the development of innovative cancer treatments. The company is currently developing a new cancer drug that aims to overcome chemotherapy resistance. Relmada Therapeutics Inc is committed to providing innovative solutions to improve and enhance the quality of life for patients. The company relies on a strong research and development platform to develop medications targeting a variety of needs. The company is committed to continuing its research and development to provide innovative solutions that improve the treatment of chronic diseases. Answer: Relmada Therapeutics Inc is a biopharmaceutical company specializing in the development of medications for chronic pain and mental health disorders. The company is headquartered in New York, USA, and has a strong pipeline of pharmaceutical products in various clinical phases. They generate revenue through the sale of patents and partnerships with other companies, and their divisions focus on pain therapy, mental health, and oncology. They aim to provide innovative solutions to improve patient quality of life and continue research and development for better treatment options. Relmada Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Relmada Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Relmada Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Relmada Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Relmada Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Relmada Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Relmada Therapeutics Stock

What is the price-to-earnings ratio of Relmada Therapeutics?

The price-earnings ratio of Relmada Therapeutics is currently -0.99.

How has the price-earnings ratio of Relmada Therapeutics changed compared to last year?

The price-to-earnings ratio of Relmada Therapeutics has increased by 19.28% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Relmada Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Relmada Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Relmada Therapeutics affect the company?

An increase in the price-earnings ratio of Relmada Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Relmada Therapeutics affect the company?

A decrease in the price-earnings ratio of Relmada Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Relmada Therapeutics?

Some factors that influence the price-earnings ratio of Relmada Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Relmada Therapeutics pay?

Over the past 12 months, Relmada Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Relmada Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Relmada Therapeutics?

The current dividend yield of Relmada Therapeutics is .

When does Relmada Therapeutics pay dividends?

Relmada Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Relmada Therapeutics?

Relmada Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Relmada Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Relmada Therapeutics located?

Relmada Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Relmada Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Relmada Therapeutics from 6/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/4/2024.

When did Relmada Therapeutics pay the last dividend?

The last dividend was paid out on 6/4/2024.

What was the dividend of Relmada Therapeutics in the year 2023?

In the year 2023, Relmada Therapeutics distributed 0 USD as dividends.

In which currency does Relmada Therapeutics pay out the dividend?

The dividends of Relmada Therapeutics are distributed in USD.